Skip to page contentSkip to Rheumatology main navigationSkip to Alendronate and Risedronate linksSkip to Allopurinol linksSkip to organizational linksSkip to Intravenous Immunoglobulin (IVIG) additional information
Home    Patients/Community    Health Professionals    Businesses    Media    Volunteers    Job Seekers      
Park Nicollet Home Page
Home
About Us
Appointments
What Is Rheumatology?
Services
Diseases, Disorders
Medications
FAQ
Resources
Locations
Contact Us
Find a doctor or other provider
(by name, clinic or specialty)

Health Care Services
Health Advisor
Who We Are
Popular Health Interests
Stores

Rheumatology Rheumatology
Rheumatology > Medications > Intravenous Immunoglobulin (IVIG)

Intravenous immunoglobulin (IVIG)

IVIG is made up of antibodies from a large group of people. It can be helpful for severe muscle diseases (dermatomyositis and polymyositis), lupus (particularly for low blood counts) and some types of vasculitis.

The typical dose of IVIG is from 400 mg/kg to 2 grams/kg, divided over two days.

  • Side effects occur in fewer than 5 percent of patients. These include headache, chills, nausea, fatigue, muscle aches, joint aches, backaches and increased blood pressure.
  • Kidney problems are rare and usually reversible.
  • Aseptic meningitis, a noninfectious meningitis, can develop, but usually resolves on its own.
  • Transmission of a blood-borne agent (HIV, hepatitis) is extremely rare.
  • Anaphylactic reaction can occur if you have a rare deficiency of IgA, a normally present class of antibodies.

In myositis, significant increases in muscle strength are expected within weeks. In lupus, improvement in low blood counts and other disease factors are desired.

Usually, your IgA antibody level will be checked before giving IVIG to make sure you do not have a rare deficiency, which could increase the likelihood of a reaction.

Infusions are given in our infusion services (Park Nicollet Clinic—St. Louis Park, 3800 Building, second floor) by nurses familiar with its use.

,
Copyright Questions/Comments Privacy Site Usage Site Accessibility